Event Participants
Executives
3
Amit Kumar (CFO), Deepak Anand (CEO - Shalby MedTec), Jigar Todi (Investor Relations)
Analysts
3
Kashish Thakur (Elara Capital), Rajakumar Vaidyanathan (RK Investment), Tripti Shukla (Kedia Securities)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹338.6 crore | +11.6% YoY as stated by management; driven by hospital growth and 53% Medtech surge |
| Standalone (Hospital) Revenue | ₹259 crore | +7% YoY; led by Krishna, Mohali, Naroda units growing ~30% YoY |
| Medtech Revenue (Consolidated) | ~₹47 crore | +53% YoY, +17% QoQ; SMTL India grew 98% YoY, SAP US +9% YoY |
| Shalby International Revenue | ₹26.2 crore | +13% YoY; international revenue 42% of operating revenue |
| Occupied Beds / Occupancy | 701 beds / 51% | Beds +9.8% YoY (639→701); occupancy up ~600 bps; 54% excl. Gurgaon |
| Consolidated EBITDA | ₹49 crore | +1% YoY; margin compressed to 14.5% from 16.0% |
| Standalone EBITDA / Margin | ₹47.8 crore / 18.4% | Margin down 320 bps YoY (21.6% → 18.4%) on new doctor hiring costs |
| Consolidated PAT / Margin | ₹10.5 crore / 3.1% | +36% YoY (₹7.7 crore in Q1 FY26); 3.1% vs 2.5% margin |
| Standalone PAT / Margin | ₹25 crore / 9.7% | Roughly flat YoY (₹25.7 crore); 9.7% vs 10.6% margin |
| Net Debt / Gearing | ₹463 crore / 0.46x | Hospital net debt only ₹54.5 crore; no increase expected |
| Payer Mix (Hospital) | 38% insurance / 32% govt / 30% self-pay | Govt share up from 24% YoY; renegotiation of govt rates underway |
| Transplants Completed | 47 total | 41 kidney, 5 liver, 1 bone marrow during the quarter |
Geographic & Segment Commentary
Hospital Segment (Standalone): Revenue grew 7% YoY to ₹259 crore with occupancy improving ~600 bps to 51% (54% ex-Gurgaon). EBITDA margin contracted 320 bps to 18.4% due to recently deployed doctors and new specialities ramping up. Management expects the full effect of new doctor contributions, TPA renewals, and bunker revenue to lift margins toward 20% from Q2 onwards. Krishna, Mohali, and Naroda each grew ~30% YoY; Surat and Indore underperformed with active doctor recruitment underway.
Shalby International (Gurgaon): Achieved EBITDA breakeven for the first time since acquisition, posting ~7% EBITDA margin. Revenue grew 13% YoY to ₹26.2 crore with ALOS of 3.8 days, though occupancy remains low at 24%. New liver transplant and KTP doctors joined mid-quarter with full revenue contribution expected in Q2; bone marrow transplant discussions ongoing. International patient flow improved from June onwards.
Medtech (SMTL India / SAP US / Singapore): Consolidated Medtech revenue ₹47 crore (+53% YoY, +17% QoQ) with fourth consecutive quarter of positive consolidated EBITDA (
₹1.7 million). SMTL India delivered ₹36 crore revenue (+98% YoY) with volume growth over 100%, and EBITDA surged 191% sequentially. SAP US remained flat on volumes with marginally negative EBITDA. Singapore entity (SDPPL) reported improving EBITDA (₹5.8 million). Inventory/DSO optimization underway targeting 30% improvement in holding period.
Company-Specific & Strategic Commentary
Medtech Cost & Margin Transformation: Multiple vendor and sourcing initiatives already reduce monthly cash inflow requirement by ~₹3 crore; a further ₹3 crore/month reduction expected after a supply-chain project completes by Q4 FY27. Gross margins guided to improve 100–200 bps per quarter, targeting double-digit EBITDA margins.
TPA Renewals & Payer Rate Renegotiation: Active TPA renewals hold potential 5–7% revenue upside. Krishna unit secured super-specialty government rates; Gurgaon follows CGHS at better rates under NABH accreditation. Bunker treatments now covered under government schemes.
Tax Optimization: Hospital segment transitioned to new tax regime (26% vs 35%). Group effective tax rate fell from 66% to 47% YoY. Carried forward losses at certain entities expected to result in zero tax expense for next 2–3 years as PBT flows through.
Capex Discipline: ~₹150 crore capex (including Ankur specialty) largely completed; management expects minimal additional capex, aiding ROE recovery to 11–13% within 1–2 years from current ~7% group / 9.5% standalone ROE.
Debt Restructuring: New ₹129 crore Kotak working capital facility is a replacement at ~50 bps lower cost than average, not incremental debt; net debt expected stable-to-declining.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Standalone EBITDA Margin | ~20% (FY27 exit rate) | Driven by TPA renewals (5–7% revenue upside), bunker revenue, new doctor ramp, Gurgaon improving contribution |
| Shalby International Occupancy | 30%+ by Q3/Q4 FY27 | Specialty additions (liver transplant, KTP) and international patient recovery from June |
| Shalby International PBT | Positive within 6–9 months | Already EBITDA positive at 7%; scale and specialties to drive PBT positivity |
| Medtech EBITDA Margin | Double-digit (post-Q4 FY27 initiatives) | Vendor/sourcing changes saving ₹3 crore/month now, another ₹3 crore/month by Q4; gross margins +100–200 bps/quarter |
| Group ROE | 11–13% within 1–2 years | Capex cycle complete; no further debt infusion expected into hospitals/Medtech |
| Effective Tax Rate | ~47% declining to near-zero tax for 2–3 years | Carried forward losses offsetting PBT; new 26% tax regime at hospital level |
Risks & Constraints
| Risk | Context |
|---|---|
| ICRA Rating Downgrade | Long-term credit rating cut from A+ to A for ₹830 crore facility in late July 2026, though outlook improved from negative to stable. Management calls it procedural and expects reassessment in coming quarters. |
| US Medtech Profitability | SAP US remains marginally EBITDA negative with flat volumes. Regulatory-driven supply chain changes require 6–9 months (to Q4 FY27) before full benefit flows through. |
| Forex Volatility | Q1 FY27 Medtech bottom line hurt versus Q4 FY26 which had one-off forex gains. Deterioration in Medtech losses (₹7.4 crore → ₹11.4 crore QoQ) partly attributable to FX swings. |
| Government Payer Shift | Government scheme share rose from 24% to 32% YoY, compressing yield (ALOS down to ₹44,711 from ₹45,673). Longer receivables from govt payers mitigated through automated collections platforms, rate renegotiations, and active recovery follow-up. |
| Interest & Depreciation Drag | Medtech bottom line impacted by elevated depreciation on intangibles/capex from prior years; interest expense now stabilizing as debt plateaued. |
Q&A Highlights
Hospital Margin Sustainability & Growth Drivers
- Question: Will standalone hospital EBITDA margins (back to ~18.4%) sustain or improve? (Rajakumar Vaidyanathan)
- Answer: Confident of improved margins in subsequent quarters. Drivers: bunkers deployed last year activate fully; TPA renewals underway offering 5–7% revenue potential; Gurgaon now EBITDA positive; Krishna/Mohali/Naroda growing ~30% YoY; Surat/Indore underperforming but doctor recruitment in active discussion. (Amit Kumar)
Medtech Bottom-Line Deterioration
- Question: Despite revenue rising YoY (₹28 crore → ₹42 crore), why did the bottom line worsen (loss ₹7.4 crore → ₹11.4 crore QoQ)? (Rajakumar Vaidyanathan)
- Answer: One-off forex gains existed in the prior quarter. Interest expense has stabilized as debt plateaued; full-year depreciation on intangibles and earlier capex now flowing. Bottom line not expected to worsen; gross margins should improve 100–200 bps per quarter. (Amit Kumar)
Deferred Tax Asset Recognition
- Question: Why is DTA not being recognized on losses, vitiating effective tax rate? (Rajakumar Vaidyanathan)
- Answer: DTA is already recognized in the hospital segment. For US Medtech, on a conservative basis DTA is not recognized currently; will be reconsidered once profitability improves. (Amit Kumar)
Medtech Path to Double-Digit EBITDA Margin
- Question: What is driving weak profitability (EBITDA ~₹1.6 million on 53% revenue growth), especially in US, and when will double-digit margins arrive? (Kashish Thakur)
- Answer: Large part of profitability decline is forex (USD/INR). India volumes grew over 100%; US volumes flat. Major initiatives already cut monthly cash inflow requirement by ~₹3 crore; another ₹3 crore/month reduction from a supply-chain project by Q4 FY27. Regulatory changes take 6–9 months; half the progress is made, double-digit EBITDA achievable from there. (Deepak Anand)
Standalone Margins, FY27 Guidance & Shalby International
- Question: What caused the ~320 bps standalone margin decline, and can you reinstate FY27 guidance? Also on Shalby International, what are occupancy/EBITDA aspirations and when will breakeven be achieved? (Kashish Thakur)
- Answer: Margin pressure is temporary from newly deployed doctors/specialties requiring ~a quarter to be fully profitable. Strongly confident of ~20% EBITDA margin on a year-on-year basis as bunker revenue and TPA renewals flow in. For Shalby International: occupancy expected to reach 30%+ from Q3/Q4 FY27; PBT positive in 6–9 months given 7% EBITDA achieved and specialty ramp-up. (Amit Kumar)
Tax Rate Guidance
- Question: What tax rate should we expect for FY27? (Kashish Thakur)
- Answer: Hospital segment already transitioned to new 26% tax scheme (from 35%). Group effective tax rate fell from 66% to 47% YoY. With carried forward losses flowing to PBT, expect no tax expense for 2–3 years — a direct cash benefit improving overall profitability. (Amit Kumar)
ROE Recovery & Mumbai Expansion
- Question: Consolidated ROE is still low (~7%); what are the levers and timelines for doubling? And how is the Mumbai expansion progressing? (Kashish Thakur)
- Answer: Standalone ROE is 9.5%, group ~7%, suppressed by heavy capex (₹150 crore including Ankur specialty) in recent years. With capex cycle complete and no further debt infusion, ROE expected to reach industry standard 11–13% within 1–2 years. Mumbai expansion: discussions ongoing with trustees; will be informed once approvals align. (Amit Kumar)
ICRA Downgrade & Kotak Facility
- Question: What drove the ICRA downgrade from A+ to A for the ₹830 crore facility, and how is debt being managed alongside the ₹129 crore Kotak working capital facility? (Tripti Shukla)
- Answer: Rating now at A with outlook improved from negative to stable — a procedural assessment subject to re-evaluation in coming quarters. The Kotak facility is a replacement of existing debt at ~50 bps lower cost, not new debt; net debt levels will not increase and should stabilize or decline. (Amit Kumar)
Government Payer Mix & Cash Conversion
- Question: Government payor mix jumped from 24% to 32% YoY while ALOS compressed; is this a structural shift, and how is cash conversion protected? (Tripti Shukla)
- Answer: Government share increased but rate renegotiations are active — Krishna unit secured super-specialty rates; Gurgaon follows CGHS at better rates. Bunkers now covered under government schemes. Cash conversion protected via automated collection platforms, prompt bill submission, and active government office follow-up visits. (Amit Kumar)
Key Takeaway
Shalby delivered a mixed Q1 FY27 with consolidated revenue up 11.6% YoY to ₹338.6 crore and PAT up 36% to ₹10.5 crore, offset by EBITDA margin compression to 14.5% (from 16%) on doctor hiring and Medtech costs. The hospital segment grew 7% with occupancy up 600 bps to 51%, though standalone EBITDA margin slipped 320 bps to 18.4%. Key strategic milestones: Shalby International's first-ever EBITDA breakeven, fourth consecutive quarter of positive Medtech consolidated EBITDA, and SMTL India revenue up 98% YoY. Management guides to ~20% standalone EBITDA margins via TPA renewals and bunker revenue, double-digit Medtech EBITDA after supply-chain initiatives complete by Q4 FY27, and Shalby International PBT positivity within 6–9 months. Watch items include the ICRA downgrade to 'A', US Medtech negative EBITDA on flat volumes and forex swings, and elevated group tax rate of 47% (to be offset by carried-forward loss utilization over 2–3 years), while ROE recovery to 11–13% is expected within 1–2 years as the capex cycle concludes.